AI
RAPT

ArchPoint Investors’s RAPT Therapeutics RAPT Stock Holding History

ArchPoint Investors’s Portfolio RAPT Stock Details RAPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-67
Closed -$12K – 99
2021
Q1 		$12K Hold
67
– – ﹤0.01% 125
2020
Q4 		$11K Buy
+67
New +$14.6K ﹤0.01% 118

Other funds holding RAPT

CG
Column Group San Francisco, California $101M AUM 290.34% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PM
Ponoi Management San Francisco, California $73.2M AUM 23.44% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
KXA
KPCB XV Associates Menlo Park, California $35.8M AUM 57.59% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
ROTUOC
Regents of the University of California Oakland, California $3.01B AUM 11.91% 1-Year Est. Return

ArchPoint Investors's RAPT Position: Q2 2021 in Review

ArchPoint Investors sold out of RAPT Therapeutics (RAPT) in Q2 2021, closing a stake of 67 shares — an estimated $12K sold.

ArchPoint Investors first reported a position in RAPT in Q4 2020 and held it in 2 quarters. The position peaked at $12K in Q1 2021. 109 funds tracked by Wall St. Rank hold RAPT as of Q2 2021.

  • ArchPoint Investors reported no remaining RAPT Therapeutics position as of Q2 2021 after selling out during the quarter.
  • ArchPoint Investors sold 67 RAPT Therapeutics shares in Q2 2021, an estimated $12K.
  • ArchPoint Investors first reported a position in RAPT Therapeutics in Q4 2020 and held it in 2 quarters.
  • ArchPoint Investors's RAPT Therapeutics position peaked at $12K in Q1 2021.
  • 109 funds tracked by Wall St. Rank held RAPT Therapeutics as of Q2 2021.

Based on ArchPoint Investors's 13F filing for Q2 2021, filed 13 Aug 2021.